<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513968</url>
  </required_header>
  <id_info>
    <org_study_id>HB110_HB_I</org_study_id>
    <nct_id>NCT00513968</nct_id>
  </id_info>
  <brief_title>Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine</brief_title>
  <official_title>A Single Center, Randomized, Open-label, Dose Escalating Phase I Study to Evaluate the Safety of Intramuscularly Administered DNA Vaccine (HB-110) Combined With Oral Antiviral (Adefovir) in Subjects With Chronic Hepatitis B Over a 48-week Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of a novel mixed plasmid DNA (HB-110)
      combined with an antiviral agent (Adefovir) for the patients with chronic Hepatitis B
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and clinical laboratory abnormalities</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBeAg/HBsAg seroconversion rate, HBV Ag specific T cell immunity</measure>
    <time_frame>24, 28, 32, 42, 44, and 48 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HB-110 2mg, 4mg or 8mg combined with Adefovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adefovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>a mixed plasmid DNA (HB-110)</intervention_name>
    <description>HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
    <description>Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatitis B infected patient documented with positive HBsAg for 3 months and
             more at screening

          -  Chronic hepatitis B infected patient with positive HBeAg at screening

          -  Patient who has not treated with interferon alpha, lamivudine or adefovir within 3
             months before study entry

          -  HBV DNA more than 1x10^5 copies/mL through COBAS Amplicor HBV monitor assay or bDNA
             method at screening

          -  Patient with HBV DNA decrease more than 10-fold compared to the baseline after 8 weeks
             treatment with adefovir

          -  Patient with ALT value between ULN x 1.5 and ULN x 5 at screening

          -  Patient given a written consent voluntarily

        Exclusion Criteria:

          -  Have uncompensated liver disease

          -  Serum creatinine &gt; ULN x 1.5

          -  Are positive for Hepatitis C, hepatitis D or HIV infection (confirmed by ELISA assay)

          -  Had a previous liver or bone marrow transplant

          -  Are currently taking any immunosuppressant or any possible immune modulatory drugs

          -  Women who are pregnant or breastfeeding

          -  Woman or man who plans a birth for study duration

          -  Any experience of severe adverse drug reaction or any medical history of severe
             allergic disease

          -  Patient with any severe disease (for example, heart failure, renal failure,
             pancreatitis, diabetes mellitus) affecting the study in discretion of investigator
             except liver disease

          -  Patient with any other liver disease but hepatitis B (for example, hemochromatosis,
             Wilson's disease, alcoholic/non-alcoholic liver diseae)

          -  Patient with intrahepatic tumors confirmed by imaging (liver biopsy)and abnormally
             increased alpha-fetoprotein

          -  Patient with any present malignant tumor except liver or its history

          -  Other inappropriate patient in discretion of investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Seung-kyu Yoon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Gastroenterology at Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>August 3, 2012</last_update_submitted>
  <last_update_submitted_qc>August 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

